Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 3 | Breast Cancer Research

Fig. 3

From: Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial

Fig. 3

Relative reduction of PAM50 proliferation score in Luminal A/B disease. a The 11-gene proliferative score at baseline vs. surgery. b Changes in the proliferation score in each arm. c Primary results of the study: On the left, the anti-proliferative effect of the combination of mVNB and LTZ vs. both monotherapy arms combined. On the right, comparison of the anti-proliferative effect between each treatment arm. Error bars indicate 95% confidence interval

Back to article page